A Phase 1, Single- and Multiple-Dose Study to Assess the Safety and Pharmacokinetics of Ixekizumab (LY2439821) (Anti-IL-17 Humanized Antibody) in Chinese Patients With Psoriasis Vulgaris
Phase of Trial: Phase I
Latest Information Update: 19 May 2017
At a glance
- Drugs Ixekizumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 17 May 2017 Status changed from not yet recruiting to recruiting.
- 04 Apr 2017 Planned initiation date changed from 30 Mar 2017 to 4 Apr 2017.
- 10 Mar 2017 New trial record